Abstract:

Objective To investigate the therapeutic effects and adverse effects of gemeitabine plus carboplatin in treatment of recurrent epithelial ovarian cancer. Methods Gemeitabine (1 000 mg/m2) was intravenously administered to 76 patients with recurrent epithelial ovarian cancer on day 1 and day 8. Carboplatin was intravenously administered on day 1 with area under the concentration-time curve of 5. Each course of treatment lasted for 21 d. The efficacy was evaluated by Response Evaluation Criteria in Solid Tumors of World Health Organization and Ovarian Cancer Therapeutic Effect Criteria of International Society of Gynecologic Cancer, and adverse effects after chemotherapy were observed. Results Among the 76 patients, complete remission was achieved in 21(27.63%), partial remission in 36(47.37%), stable disease in 13（17.11%） and progression disease in 6（7.89%）. The overall response rate was 75.0%(57/76). The mean progression-free survival was 4.1 months (2 to 10 months). Eight days after chemotherapy, the prevalences of neutropenia, thrombocytopenia, anemia and gastrointestinal adverse effects were 84.21%, 78.95%, 26.32% and 86.84%, respectively, and the prevalence of each of the other adverse effects was less than 20%. No death occurred. Conclusion Gemeitabine plus carboplatin is an effective regimen for treatment of recurrent recurrent epithelial ovarian cancer, with favorable therapeutic effects, high safety and tolerable adverse effects.

Key words: gemcitabine, carboplatin, recurrent epithelial ovarian cancer, chemotherapy